<DOC>
	<DOCNO>NCT00594984</DOCNO>
	<brief_summary>Part 1 : To define recommend dose brivanib safely administer combination Erbitux ( Cetuximab ) irinotecan subject advance metastatic colorectal cancer ( MCRC ) Part 2 : To compare median duration progression free survival ( PFS )</brief_summary>
	<brief_title>Phase I/II Combination With Irinotecan- Erbitux</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Biopsy proven MCRC Prior irinotecan allow Prior Erbitux allow No prior brivanib No prior combination irinotecan Erbitux No secondary malignancy No anticoagulation therapy No prior history blood clot require anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>